Here are the 10-K annual reports from Nordicus Partners Corporation (NORD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow NORD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NORD filings page.
Nordicus Partners Corporation is a U.S.-listed biotech focused on acquiring and developing Nordic-origin drugs for diseases with unmet medical needs, initially in oral disorders and psoriasis. For the year ended March 31, 2026 it generated no revenue (versus $5,000 a year earlier) and reported a net loss attributable to the company of $4.0 million, or $0.22 per share, driven by higher R&D and corporate expenses.
Operating expenses were $4.37 million, including $1.61 million of research and development across three preclinical programs: Orocidin’s QR-01 for periodontitis, Bio-Convert’s QR-02 for oral leukoplakia, and NoviThera’s QR-04 for psoriasis. QR-01 showed efficacy in dog and rat models and QR-02 received a toxicity waiver and is moving toward GMP production, with both programs anticipating Phase IIa trials in the first half of 2027. NoviThera achieved biological proof of concept in a mouse study.
Liquidity is constrained: cash was only $20,878 at March 31, 2026 after using $4.32 million in operating cash flows, largely offset by $4.34 million raised from equity issuances. The independent auditor cited nominal revenue, recurring losses and an accumulated deficit as raising substantial doubt about Nordicus’s ability to continue as a going concern. Management is seeking additional capital and has applied to uplist its shares to the Nasdaq Capital Market.